A faster one To update on the status of the state-level psychedelics bills discussed on May 12:

• Arizona: Gov. Katie Hobbs (D) approved the proposed budget SB 1720 including a $5 million psilocybin research funding agreement and advisory board. Related SB 1726 establishes details for psilocybin clinical trials.
  Both measures passed the Senate on May 10, while the House of Representatives initially approved companion versions of the bill. Full passage is expected soon, reported marijuana moment.
  SB 1726 states that research grants will be awarded for DEA approval phase 1, 2 and 3 clinical trials of whole mushroom psilocybin targeting conditions such as PTSD, long-term COVID-19, depression and anxiety disorders.
  
  Connecticut: HB 6734 Downgrading the crime rate of up to 1.5 ounces of psilocybin and promoting a drug education program was approved by the House Plenary on May 10 and will move to the Senate.

• Maine: LD 1914 or “The Maine Psilocybin Health Access Act,” which seeks to establish a psilocybin therapy program for adults over 21, was referred by the House and Senate to the Veterans and Judiciary Committee on May 9th.

In the meantime, LD 1467 The creation of the Maine Cannabis Research Committee and a call for a review of potential uses of “complementary alternative medicine” including psilocybin, ketamine and MDMA were defeated in the Senate on May 9th.

• Vermont: The Judiciary of the House of Representatives held a committee hearing for discussion on May 4th H371 calls for the legalization of psilocybin and the establishment of an advisory working group on psychedelics in 2024, reported marijuana moment. The measure has an accompanying draft law, S 114currently in the Senate.

• Missouri: HB 1154 Towards government research on psilocybin in depression, post-traumatic stress disorder, substance use disorders and end-of-life care, after much movement May 5th is on the informal calendar, meaning the sponsor of the bill can bring it up again in the upcoming session…